Biosimilars in Belgium: a proposal for a more competitive market

References

• Memorandum. Strombeek-Bever: Medaxes; 2019.
   Google Scholar
• Download medicine data | European Medicines Agency: European Medicines Agency; [cited 2020 Feb]. Available from: https://www.ema.europa.eu/en/medicines/download-medicine-data.
   Google Scholar
• BCFI | Startpagina: Belgisch Centrum voor Farmacotherapeutische Informatie; [ cited 2020 Jan]. Available from: https://www.bcfi.be/nl/start.
   Google Scholar
• Moorkens E, Vulto A, Huys I An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry? [Unpublished]. 2020.
   Google Scholar
• De prijsdalingsmaatregel voor de “oude geneesmiddelen” en de “volumecliff” (The price decrease measure for “old medicines” and the “volume cliff”): RIZIV/INAMI/NIHDI; 2019; [cited 2020 Jan] Available from: https://www.inami.fgov.be/nl/themas/kost-terugbetaling/door-ziekenfonds/geneesmiddel-gezondheidsproduct/terugbetalen/specialiteiten/Paginas/prijsdalingsmaatregel-oude-geneesmiddelen.aspx.
   Google Scholar
• De prijsdalingsmaatregel voor de biologische geneesmiddelen (The price decrease measure for biological medicines): RIZIV/INAMI/NIHDI; 2019; [cited 2020 Jan]. Available from: https://www.inami.fgov.be/nl/themas/kost-terugbetaling/door-ziekenfonds/geneesmiddel-gezondheidsproduct/terugbetalen/specialiteiten/Paginas/prijsdalingsmaatregel-biologische-geneesmiddelen.aspx.
   Google Scholar
• Prijsdalingen en lijst goedkoopsten [Price decreases and list of low-cost medicines]: Brabants Apothekers Forum (BAF); 2020; [ cited 04]. Available from: https://baf.be/diensten/tarifering-helpdesk/prijsdalingen-en-lijst-goedkoopsten.
   Google Scholar
• Omzendbrief actieplan biosimilars (Circular letter action plan biosimilars): RIZIV/INAMI/NIHDI; 2016; [cited 2019 Nov]. Available from: https://www.inami.fgov.be/SiteCollectionDocuments/omzendbrief_actieplan_biosimilar.pdf.
   Google Scholar
• Terugbetaling van geneesmiddelen: wat is gewijzigd sinds 1 april 2019 (Reimbursement of medicines: changes from 1 April 2019): RIZIV/INAMI/NIHDI; 2019; [ cited Nov]. Available from: https://www.inami.fgov.be/nl/professionals/andere-professionals/farmaceutische-industrie/Paginas/terugbetaling-geneesmiddelen-01042019.aspx#Daling_tot_85%_voor_de_facturatie_van_bepaalde_geneesmiddelen_in_het_ziekenhuis.
   Google Scholar
• Lepage-Nefkens I, Gerkens S, Vinck I, et al. Barriers and opportunities for the uptake of biosimilar medicines in Belgium. Health Services Research (HSR) Brussels: belgian Health Care Knowledge Centre (KCE); 2013. Report No.: KCE Report 199. D/2013/10.273/13 Contract No.: KCE Report 199. D/2013/10.273/13.
   Google Scholar
• ‘Goedkoop voorschrijven’ (Low-cost prescribing): RIZIV/INAMI/NIHDI; 2018; [cited Nov 2019]. Available from: https://www.riziv.fgov.be/nl/professionals/individuelezorgverleners/artsen/verzorging/Paginas/goedkoop-voorschrijven-20150101.aspx#.WTh9WdwlHIU.
   Google Scholar
• Dylst P, Vulto A, Simoens S. Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. Pharmacoeconomics. 2014;32(7):681–691.
   Google Scholar
• Biosimilars: FAGG/AFMPS/FAMHP; 2009; [cited 2019 Nov]. Available from: https://www.famhp.be/en/human_use/medicines/medicines/MA_procedures/types/Biosimilars.
   Google Scholar
• Switch and substitution of biological medicinal products: FAGG/AFMPS/FAMHP; 2009; [cited 2019 Nov]. Available from: https://www.famhp.be/en/switch_and_substitution_of_biological_medicinal_products.
   Google Scholar
• Convenant “Doorstart voor biosimilaire geneesmiddelen in België” (Convenant on the use of biosimilar medicines in Belgium): RIZIV/INAMI/NIHDI; 2018; [cited 2019 Nov]. Available from: https://www.inami.fgov.be/nl/themas/kost-terugbetaling/door-ziekenfonds/geneesmiddel-gezondheidsproduct/geneesmiddel-voorschrijven/Paginas/biosimilaire-geneesmiddelen.aspx.
   Google Scholar
• Biosimilaire geneesmiddelen: aanzienlijke besparingen voor het gezondheidszorgsysteem (Biosimilar medicines: significant savings for the healthcare system): RIZIV/INAMI/NIHDI; 2018; [ cited 2020 Jan]. Available from: https://www.inami.fgov.be/nl/themas/kost-terugbetaling/door-ziekenfonds/geneesmiddel-gezondheidsproduct/geneesmiddel-voorschrijven/Paginas/biosimilaire-geneesmiddelen-belangrijk-besparingen.aspx.
   Google Scholar
• Omzendbrief Opname van biosimilaire geneesmiddelen in het therapeutisch formularium (TF) door het Medisch-Farmaceutisch Comite (MFC) in uitvoering van de wetgeving op de overheidsopdrachten (Circular letter on the use of biosimilars in the therapeutic protocol of the Medical-Pharmaceutical Committee for the implementation of the law on public procurement): RIZIV/INAMI/NIHDI; 2016; [cited 2019 Nov]. Available from: https://www.inami.fgov.be/SiteCollectionDocuments/omzendbrief_biosimilaire_geneesmiddelen_ziekenhuis.pdf.
   Google Scholar
• Archief presentaties (Archived presentations): FAGG/AFMPS/FAMHP; 2018; [cited 2019 Nov]. Available from: https://www.fagg.be/nl/2018_archief_presentaties.
   Google Scholar
• Nieuwe campagne om patiënten te informeren over biologische geneesmiddelen en om het voorschrijven van biosimilaire geneesmiddelen aan te moedigen. (New campaign to inform patients about biological medicines and encourage the prescription of biosimilars.): FAGG/AFMPS/FAMHP; 2018; [cited 2019 Nov]. Available from: https://www.fagg.be/nl/news/nieuwe_campagne_om_patienten_te_informeren_over_biologische_geneesmiddelen_en_om_het.
   Google Scholar
• Informatiecampagne om patiënten te informeren over biologische geneesmiddelen en om het voorschrijven van biosimilaire geneesmiddelen aan te moedigen. (Information campaign to inform patients about biological medicines and to encourage the prescription of biosimilars.): RIZIV/INAMI/NIHDI; 2018; [cited 2019 Nov]. Available from: https://www.riziv.fgov.be/nl/pers/Paginas/biosimilaire-geneesmiddelen.aspx.
   Google Scholar
• Biologische en biosimilaire geneesmiddelen (Biological and biosimilar medicines): FAGG/AFMPS/FAMHP; 2018; [cited 2019 Nov]. Available from: https://www.faggcampagnes.be/nl/biologische-en-biosimilaire-geneesmiddelen.
   Google Scholar
• Koninklijk besluit tot vaststelling van de procedures, termijnen en voorwaarden inzake de tegemoetkoming van de verplichte verzekering voor geneeskundige verzorging en uitkeringen in de kosten van farmaceutische specialiteiten (Royal Decree laying down the procedures, terms and conditions for the reimbursement of the mandatory insurance for medical care and in the costs of pharmaceutical specialties): Belgisch Staatsblad; 2018; [cited 2019 Nov]. Available from: http://www.ejustice.just.fgov.be/cgi_loi/change_lg.pl?language=nl&la=N&cn=2018020122&table_name=wet.
   Google Scholar
• Biosimilaire geneesmiddelen: incentive voor het voorschrijven van biosimilaire geneesmiddelen buiten het ziekenhuis (Biosimilars: incentive to prescribe biosimilars in the outpatient setting): RIZIV/INAMI/NIHDI; 2019; [cited 2019 Nov]. Available from: https://www.inami.fgov.be/nl/themas/kost-terugbetaling/door-ziekenfonds/geneesmiddel-gezondheidsproduct/geneesmiddel-voorschrijven/Paginas/biosimilaire-geneesmiddelen-buiten-ziekenhuis.aspx.
   Google Scholar
• Biosimilars newsletter September 2019: Medaxes; 2019; [cited 2019 Nov]. Available from: https://www.medaxes.be/nl/actualiteit/biosimilars-newsletter.
   Google Scholar
• Omzendbrief nr. 646: FAGG/AFMPS/FAMHP; 2019; [cited 2019 Nov]. Available from: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=2ahUKEwiIotPep43mAhUQblAKHYC2DH0QFjAAegQIBRAC&url=https%3A%2F%2Fwww.fagg.be%2Fsites%2Fdefault%2Ffiles%2Fcontent%2FDC-CT%2F20190625151700.pdf&usg=AOvVaw3vQ8Lp4w3QZCWtvAmVFHNq.
   Google Scholar
• Advies van de commissie voor de overheidsopdrachten betreft verenigbaarheid van premies of voordelen als gunningscriterium (Advice of the commission for public procurement concerning compatibility of premiums or benefits as an award criterion): Publicprocurement.be; 2019; [cited 2019 Nov]. Available from: https://www.publicprocurement.be/nl/documenten/verenigbaarheid-van-premies-voordelen-als-gunningscriterium.
   Google Scholar
• De begroting van de verzekering voor geneeskundige verzorging in 2020 (The budget for the insurance of medical care in 2020): RIZIV/INAMI/NIHDI; 2019; [cited 2020 Jan]. Available from: https://www.riziv.fgov.be/nl/nieuws/Paginas/begroting-geneeskundige-verzorging-20191122.aspx.
   Google Scholar
• Belgium: an innovative pharma valley in Europe Brussels: pharma.be; 2019; [cited 2020 Feb]. Available from: https://pharma.be/nl/component/attachments/?task=download&id=580:Broch.
   Google Scholar
• TED Tenders Electronic Daily: European Union; 2020; [cited 2020 Jan]. Available from: https://ted.europa.eu/TED/browse/browseByMap.do.
   Google Scholar
• Improving healthcare delivery in hospitals by optimized utilization of medicines - A study into 8 European countries. KPMG Advisory N.V. Commissioned by Medicines for Europe. 2019.
   Google Scholar
• Broens B. Huiszoekingen in de farmasector (Searches in the pharmaceutical sector): De Tijd; 2019; [cited 2020 Jan]. Available from: https://www.tijd.be/ondernemen/farma-biotech/huiszoekingen-in-de-farmasector/10169639.html.
   Google Scholar
• Ook ziekenhuizen in vizier mededingingsautoriteit (Also hospitals targeted by the competition authority): De Specialist; 2019; [cited 2020 Jan]. Available from: https://www.despecialist.eu/nl/nieuws/ook-ziekenhuizen-in-vizier-mededingingsautoriteit.html.
   Google Scholar
• Nederlandstalige Ondernemingsrechtbank Brussel - Vonnis (Dutch Brussels enterprise court -judgement): IEFbe; 2019; [cited 2020 Jan] Available from: http://ie-forum.be/documents/ecli/5dbc3f24-a054-4bd2-83bf-2a97c35ff8c2.pdf.
   Google Scholar
• EP2055313 - Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody European Patent Register: European Patent Office; 2020; [cited 2020 Jan]. Available from: https://register.epo.org/application?number=EP09002504&tab=main.
   Google Scholar
• EP1951304 - METHOD FOR TREATING JOINT DAMAGE European Patent Register: European Patent Office; 2020. [cited 2020 Jan]. Available from: https://register.epo.org/application?number=EP06837634&tab=main.
   Google Scholar
• BCFI - start: Belgisch Centrum voor Farmacotherapeutische Informatie (BCFI); 2020; [cited 2020 Jan]. Available from: https://www.bcfi.be/nl/start.
   Google Scholar
• Dutta B, Huys I, Vulto AG, et al. Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs. 2019. DOI:https://doi.org/10.1007/s40259-019-00395-w
   Google Scholar
• Shina S, Derbyshire M. Patent expiry dates for biologicals: 2018 update. GaBI J. 2019;8(1):24–31.
   Google Scholar
• Medicines under evaluation: European Medicines Agency; 2020; [cited 2020 Feb]. Available from: https://www.ema.europa.eu/en/medicines/medicines-under-evaluation.
   Google Scholar
• Moorkens E, Simoens S, Troein P, et al. Different policy measures and practices between Swedish counties influence market dynamics: part 2-biosimilar and originator etanercept in the outpatient setting. BioDrugs. 2019;33(3):299–306.
   Google Scholar
• Biosimilar medicines: case studies: NHS Scotland; 2016; [cited 2019 Oct]. Available from: http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/adtc_resources/biosimilar_meds_case_studies.aspx.
   Google Scholar
• Grotere rol poliklinische apotheek bij TNF-alfaremmers [Greater role for hospital pharmacy for outpatients for TNF-alpha inhibitors]: Stichting Farmaceutische Kengetallen; 2013; [cited 2020 Jan]. Available from: https://www.sfk.nl/publicaties/PW/2013/grotere-rol-poliklinische-apotheek-bij-tnf-alfaremmers.
   Google Scholar
• Moorkens E, Vulto A, Huys I. Biosimilars. Regulatory frameworks for marketing authorisation of biosimilars: where do we go from here? Eur Pharm Law Rev. 2018;2(3):149–154.
   Google Scholar
• Het Biosimilars Nederland/IVM project: Biosimilars op Maat (BOM) [The Biosimilars Nederland/IVM project: A taillored approach to biosimilars]: Biosimilars Nederland; 2019; [cited 2020 Jan]. Available from: https://www.biosimilars-nederland.nl/het-biosimilars-nederland-ivm-project-biosimilars-op-maat-bom/.
   Google Scholar
• Biosimilars Op Maat [A tailored approach to biosimilars]: Instituut Verantwoord Medicijngebruik; 2020; [cited 2020 Jan]. Available from: https://www.medicijngebruik.nl/projecten/biosimilars-op-maat.
   Google Scholar
• Commissioning intentions: adalimumab: NHS England; 2018; [cited 2020 Jan]. Available from: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=12&cad=rja&uact=8&ved=2ahUKEwjf28S3mK7nAhXFnFwKHYFECYsQFjALegQIBBAB&url=https%3A%2F%2Fwww.sps.nhs.uk%2Fwp-content%2Fuploads%2F2018%2F09%2F20180925-Contractual-Commissioning-Intentions-Adalimumab_corporate-template.pdf&usg=AOvVaw3_UBUjJ57R5TQKGZQjV7e7.
   Google Scholar
• Mack A. Norway, biosimilars in different funding systems: what works? GaBI J. 2015;4(2):90–92.
   Google Scholar
• Vermeire S, Louis E, Dewit O, et al. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD). Acta Gastroenterol Belg. 2015;78(1):26–29.
   Google Scholar
• Westhovens R. Biosimilars in Rheumatic Diseases. Position of the Royal Belgian Society of Rheumatology: Reumanet; 2015; [cited 2020 Jan]. Available from: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=2ahUKEwj74fCFuq7nAhXsTxUIHbGJBo8QFjABegQIBhAB&url=https%3A%2F%2Fwww.reumanet.be%2Fsites%2Fdefault%2Ffiles%2FBiosimilars%2520KBVRSRBR%2520viewpoint.pdf&usg=AOvVaw2SxSM6qazfQJPQ7NQy4MHb.
   Google Scholar
• Franchimont D, Ferrante M, Louis E, et al. Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD). Acta Gastroenterol Belg. 2018;81(1):49–53.
   Google Scholar
• Somers M, Bossuyt P, Ferrante M, et al. For B. Belgian IBD Research Group (BIRD) position statement 2019 on the use of adalimumab biosimilars in inflammatory bowel diseases. J Crohns Colitis. 2019. DOI:https://doi.org/10.1093/ecco-jcc/jjz209
   Google Scholar
• New international record for switch to biosimilar: amgros; 2019; [cited 2020 Jan]. Available from: https://amgros.dk/en/knowledge-and-analyses/articles/new-international-record-for-switch-to-biosimilar/.
   Google Scholar